|
|
||||||||
Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
| |
ABSTRACT |
|---|
|
|
|---|
A cell culture model
of bovine aortic endothelial cells attached to microcarrier beads was
used to study the interaction of diaspirin cross-linked hemoglobin (an
oxygen-carrying blood substitute) with hypoxia-reoxygenation.
Hemoglobin (200 µM) and hypoxia-volume restriction (3-5 h),
together and separately, caused toxicity in this model, as measured by
decreased cellular replating efficiency. Hemoglobin (60 µM) caused a
reduction in hydrogen peroxide concentration and an increase in lipid
peroxidation above that induced by hypoxia alone. Incubation of
hemoglobin with endothelial cells caused transient oxidation of
hemoglobin to its highly reactive and toxic ferryl species after
3 h
of hypoxia, followed by 1 h of reoxygenation. Lipid peroxidation, which
may occur in the presence of ferrylhemoglobin, also occurred after 1 h
of reoxygenation. Hemoglobin caused a dose-dependent decrease in
intracellular glutathione concentration, suggesting that it caused an
oxidative stress to the cells. However, addition of ascorbate,
-tocopherol, or trolox did not decrease hemoglobin oxidation in the
presence of normal or hypoxic cells. It is concluded that diaspirin
cross-linked hemoglobin forms a ferryl intermediate in the absence of
any exogenously added oxidant and contributes to the oxidative burden
experienced by endothelial cells after hypoxia-reoxygenation, a
condition that is likely to be encountered during trauma and surgery
when hemoglobin solutions are used as perfusion agents.
hemoglobin-based oxygen carriers; endothelium; antioxidants
| |
INTRODUCTION |
|---|
|
|
|---|
INTERACTIONS OF HEME proteins with tissue have been
suggested to occur in a variety of pathophysiological states, including blast pressure injury (19), ischemia-reperfusion (16), and cerebral hemorrhage (33). In addition, a variety of oxygen-carrying blood substitutes are being developed, based on modified forms of
hemoglobin, which also have the potential to interact with vascular
tissue (4, 15). Because the toxicity associated with exposure to native
hemoglobin has been ascribed to dissociation of hemoglobin into its
dimeric subunits, current design strategies for modified hemoglobins
include chemical and genetic manipulation to facilitate retention of
their tetrameric form (15). These modifications, which include chemical
cross-linking of either the
- or
-subunits, polymerization, and
genetic amino acid substitution, have been shown to improve the
intravascular retention of hemoglobin, to improve its oxygen
"off-loading" capabilities, and to decrease its renal toxicity.
New and more challenging problems with toxicity and efficacy remain,
however, including vasoconstriction, short intravascular half-life, and
rapid autoxidation associated with free radical-mediated toxicity,
which have been attributed to the redox properties of the heme group
(4, 15).
Little is known about the interaction of heme proteins with cellular oxidants and antioxidants in vivo or with oxidative disease states such as ischemia-reperfusion. Oxidation of hemoglobin by endothelial cells has been correlated with oxidative stress and cell injury (27). Reactions with nitric oxide (6) and hydrogen peroxide (17) have been shown to alter the oxidation states of hemoglobin, and reductants such as glutathione and ascorbate, traditionally considered to be antioxidants, can directly oxidize oxyhemoglobin in the presence of oxygen (19). The reaction of hemoglobin with an oxidant, such as hydrogen peroxide, is also expected to cause cooxidation of other cellular macromolecules, such as unsaturated lipids (21). These oxidative reactions of hemoglobins and of chemically stabilized hemoglobins make excellent tools for uncovering the mechanisms of heme-related toxicity in vivo (2, 5).
Hemoglobins exist in several oxidation states. Oxyhemoglobin (Hb2+), the oxygen-carrying form, can be autoxidized to methemoglobin (Hb3+), a reaction that can be accelerated by low concentrations of hydrogen peroxide. In the presence of hydrogen peroxide, higher oxidation products of hemoglobin may also be formed, which include ferrylhemoglobin (Hb4+), a strong oxidant that can be detected spectrophotometrically, and a transient, globin-associated radical that can only be detected by electron paramagnetic resonance spectroscopy (25, 40). Modification of hemoglobin structure, as is done during the manufacture of blood substitutes, can, in some instances, alter its tendency to form Hb4+ or extend the length of time that it remains in this oxidized state (2).
One widely studied modified hemoglobin is
-DBBF, a stroma-free human
hemoglobin, which is stabilized by cross-linking its
-chains with
bis(3,5-dibromosalicyl)fumarate (38). It has demonstrated an improved
capacity to off-load oxygen at normal tissue oxygen tensions, but it
has also exhibited altered redox activity in the presence of hydrogen
peroxide in vitro, including a prolonged capacity to remain in the
ferryl oxidation state after exposure to hydrogen peroxide (5).
Endothelial cells produce hydrogen peroxide under normal conditions and
to a greater extent after anoxia or ischemia followed by
reperfusion (24, 34, 49). Endothelial cells have been shown to be a
major site of free radical production after
ischemia-reperfusion (50), as well as a site of oxidative
damage (45) and a source of hydrogen peroxide, lipid hydroperoxides,
and nitric oxide (26, 36), which are known to react with hemoglobin.
Endothelial cells have been used as a model to study potential
oxidative mechanisms of toxicity of hemoglobin-based oxygen carriers
(18). Modified oxyhemoglobins, including
-DBBF, were shown to be
only mildly toxic in normal endothelial cells, whereas
ferrylhemoglobin, produced by the reaction of oxyhemoglobin with
hydrogen peroxide, induced rapid morphological changes and DNA
fragmentation indicative of apoptosis (18).
With the use of a model of endothelial cells grown on microcarrier beads, it is possible to restrict both oxygen and media volume (hypoxia-volume restriction) by letting the cells settle in a test tube followed by reoxygenation-volume replacement (24). Changes in lactate accumulation, pH, calcium flux, hydrogen peroxide production, fatty acid release, and lipid peroxidation have been monitored over time in this model and were found to be dependent on the length of the period of hypoxia-volume restriction (24). This model is now being used to study potential mechanisms of toxicity of hemoglobin-based oxygen carriers during ischemia-reperfusion and to monitor hemoglobin-mediated oxidative reactions. We report, for the first time, the detection of ferrylhemoglobin in a time frame that corresponds closely with peroxide production and lipid peroxidation after hypoxia followed by reoxygenation in an endothelial cell culture.
| |
METHODS |
|---|
|
|
|---|
Cell culture model. Bovine aortic endothelial cells (BAEC) were isolated from a freshly slaughtered animal, subcloned, and used before passage 13 (24). The phenotype of these cells was confirmed by the expression of factor VIII antigen, by low-density lipoprotein uptake, and by morphological examination. BAEC were grown to confluence on suspended collagen-coated Cytodex 3 beads (Sigma, St. Louis, MO) in DMEM (GIBCO) containing 10% fetal bovine serum (GIBCO), penicillin-streptomycin-neomycin mix (Sigma), 25.0 mg/l heparin, 2 mM glutamate, and 12.5 mg/l ascorbate. Hydrated Cytodex 3 microcarrier beads (0.08 g) were added to 106 cells in a culture dish, and BAEC were allowed to grow to confluence.
To imitate ischemia, 2 × 105 cells on beads were pipetted into a conical centrifuge tube and allowed to settle, and the excess media were removed to a separate flask (hypoxia-volume restriction). The headspace of the centrifuge tube was flushed with N2 containing 5% carbon dioxide and incubated at 37°C undisturbed for the specified period of time. To imitate reperfusion, the cells and beads were resuspended in the original volume of warm, normoxic medium and removed to a cell culture plate (24).Lactate analyses. Hypoxic cells were resuspended in 100 µl of PBS. Lactate levels, a defining characteristic of ischemic metabolism, were measured using a Sigma diagnostic kit (23). The content of lactate in the PBS was measured as NADH production, catalyzed by lactic dehydrogenase, using lactate and excess NAD+ as substrates. The formation of NADH was determined spectrophotometrically at 340 nm, and the assay was standardized using a lactate concentration curve. Lactate concentration was expressed as millimoles per liter of PBS per 106 cells.
Hydrogen peroxide production. Hypoxic cells were resuspended in their original oxygenated medium for 1 h. Hydrogen peroxide was measured in cell medium (1 ml) diluted with modified Hanks' balanced salt solution (2 ml), using a horseradish peroxidase assay, which measures the reaction of the enzyme with hydrogen peroxide to cooxidize p-hydroxyphenyl acetic acid (p-HPA) (34). The formation of a fluorescent complex with excitation at 323 nm and emission at 400 nm was measured using a Photon Technology International (PTI) Delta Scan (Brunswick, NJ). The assay was standardized with known quantities of hydrogen peroxide. In experiments in which hemoglobin was added to some samples in the normoxic medium, controls minus p-HPA were used to determine that hemoglobin did not interfere with the assay by directly cooxidizing p-HPA.
Measurement of cell survival (plating efficiency). Cell survival was determined after reoxygenation by measurements of 24-h plating efficiency (24). Replating efficiency was determined by pipetting aliquots of cell suspension onto 12-well plates containing fresh complete medium at 37°C followed by a 24-h incubation under standard culture conditions. The number of surviving, attached cells was determined by washing three times with PBS, trypsinizing the cultures, and counting aliquots of the cell suspension with a Coulter counter (Hileah, FL).
Glutathione concentration. Hemoglobin (0-400 µM) was incubated with 5 × 105 cells for 3 h at 37°C. The cells were then washed, trypsinized, and incubated in DMEM with 40 µM monochlorobimane for 10 min (7). Fluorescence was recorded at 461 nm using a PTI Delta Scan, with excitation set at 380 nm, as the percentage present in control cells.
Lipid peroxidation. Hypoxic cells were resuspended in their original oxygenated medium for 60 min before the final removal of the overlying medium and immediate extraction (24). The lipid extracts were analyzed at 234 nm for conjugated dienes, an indicator of lipid peroxidation (37).
Hemoglobin solution.
-DBBF hemoglobin was a gift from the Walter Reed Army Institute of
Research (Washington, DC).
-DBBF is a human-derived stroma-free hemoglobin stabilized by cross-linking of the
-subunits with bis(3,5-dibromosalicyl)fumarate as previously described (38). The
oxygen transport characteristics of
-DBBF are close to those of
human blood with a P50 of 28 mmHg.
Other functional and oxidation reaction properties of this protein have
been published previously (5). Hemoglobin concentrations were based on
heme concentration, which was determined spectrally using a Hitachi
U-2000 spectrophotometer. Multicomponent analysis was used to calculate
the percentage of oxy, met, and ferryl forms of hemoglobin (48).
Oxidation and detection of ferrylhemoglobin in endothelial cells.
Hypoxic cells were resuspended in their original oxygenated medium plus
hemoglobin. Oxidation of hemoglobin was monitored spectrophotometrically (48), during the volume replacement period, in
cells subjected to 0 or 3 h of hypoxia-volume restriction. Multicomponent analysis was used to calculate the percent of oxy, met,
and ferryl forms of hemoglobin. Ferrylhemoglobin was also detected by
its reaction with sodium sulfide
(Na2S) as it was formed from
hemoglobin in cell medium (9).
Na2S (2 mM) was added to the
normoxic medium at 60 min and incubated for 30 min before
spectrophotometric detection of sulfhemoglobin at 620 nm using a Perkin
Elmer Lambda 18 dual-beam spectrophotometer (Norwalk, CT). The
concentration of sulfhemoglobin was estimated using the extinction
coefficient of sulfmyoglobin
(
620-604nm = 10.5 mM
1 · cm
1)
(9).
Antioxidants.
-Tocopherol (100 µM) was added to BAEC during growth in 0.5%
ethanol, and the excess was washed away with fresh medium before the
initiation of hypoxia (24). Ascorbate (100 µM) or trolox (100 µM)
was added during reoxygenation in the presence of 60 µM hemoglobin.
Statistical analyses.
Data are expressed as means ± SE. Analyses were performed using
ANOVA and Student's paired t-test.
P
0.05 was considered significant.
All calculations were performed with JMP 3.2.1 (SAS Institute, Cary, NC).
| |
RESULTS |
|---|
|
|
|---|
Initial studies were done to establish dose-response curves for hypoxia
and to confirm the presence of anaerobic metabolism. Lactate production
was increased in BAEC during hypoxia, and its accumulation in cell
medium was dependent on the duration of hypoxia (Fig.
1A).
Hydrogen peroxide, a reduction product of superoxide, accumulated in
cell medium after variable periods of hypoxia followed by 1 h of
reoxygenation, and its production was also dependent on the duration of
hypoxia (Fig. 1B).
|
Toxicity curves were established for
-DBBF hemoglobin administered
during reoxygenation using an endothelial cell replating efficiency
assay (Fig. 2). Survival was defined as the
ability of endothelial cells to remain intact and attached to a culture dish for 24 h following treatment and was shown to be dependent on the
duration of hypoxia (24). The addition of 60 or 100 µM hemoglobin
during the reoxygenation period did not significantly affect the
survival of cells. The addition of
-DBBF hemoglobin (200 µM)
during reoxygenation increased the toxicity of both control cells and
cells subjected to varying periods of hypoxia-reoxygenation (Fig. 2).
|
Lipid peroxidation is a measure of oxidative stress and sublethal
toxicity. After variable periods of hypoxia, followed by 1 h of
reoxygenation, lipid peroxidation was found to be correlated with the
duration of treatment (Fig. 3). Addition of
60 µM
-DBBF hemoglobin, a concentration that was not found to
significantly affect cell survival when added during the reoxygenation
period, caused a significant increase in lipid peroxidation after
2 h of hypoxia followed by 1 h of reoxygenation. Lipid peroxidation after
hypoxia was found to be a transient phenomenon with a maximum at
1-2 h of reoxygenation in this system (data not shown). Neither desferrioxamine (200 µM) nor EDTA (100 µM) affected the magnitude of this effect (data not shown).
|
Hydrogen peroxide accumulation in cell media, as shown in Fig.
1B, was decreased in both normal and
hypoxic-reoxygenated cells by 60 µM hemoglobin (Fig.
4). This is consistent with the
reported pseudoperoxidase activity of hemoglobin. Like true
peroxidases, hemoglobin consumes hydrogen peroxide and organic
peroxides as it cycles between oxidation states (31).
|
Glutathione depletion was not observed during the early stages of
reoxygenation in this model (data not shown), possibly because of the
relatively low levels of hydrogen peroxide produced at this early stage
of reoxygenation. Three hours of incubation with hemoglobin, however,
caused depletion in a concentration-dependent manner of intracellular
glutathione (Fig. 5), an antioxidant that is involved in cellular defense against both hydrogen peroxide and
lipid hydroperoxides (7).
|
Time-dependent changes in the oxidative state of hemoglobin were
monitored in the presence of normal or hypoxic-reoxygenated cells. In
these experiments, normal or hypoxic cells were incubated with 60 µM
hemoglobin, and spectra were recorded in the visible and Soret regions
(Fig.
6A). The
oxidation of hemoglobin began immediately, as evidenced by the loss of
absorption at the 577- and 541-nm bands typical of oxyhemoglobin,
yielding a final spectrum of ferrihemoglobin at 24 h with a
characteristic absorption at 630 nm. The disappearance of the ferrous
(Fe2+) form is accompanied by a
burst in the ferrylhemoglobin, as witnessed by the appearance of a
characteristic peak at 545 nm and a flattened region between 600 and
700 nm (5), and possibly by other nonferric hemoglobin oxidation
products. Figure 7 shows the results of a subsequent multicomponent analysis in which the proportions of ferric
(Fe3+) and ferryl
(Fe4+) species only are plotted
as a function of time. Only a slight reduction in the total amount of
heme in solution, as calculated by the sum of the three hemoglobin
oxidation forms, was observed throughout the incubation period.
|
|
There was also a steady rise in methemoglobin over a 24-h period of incubation. Methemoglobin concentrations increased twice as rapidly (10.7 vs. 5.6 µM/min) in hypoxic-reoxygenated vs. normal cells and remained higher in those cells until nearly 24 h later, when most hemoglobin was in the methemoglobin state in both normal and reoxygenated cells.
The presence of ferrylhemoglobin was confirmed via its derivitization
to sulfhemoglobin using Na2S (9).
Na2S was added to the culture
medium at 60 min or at 20 h of reoxygenation, and sulfhemoglobin formed
via reaction of ferrylhemoglobin with
Na2S was measured at 620 nm (Fig.
6B). No changes in endothelial
morphology were observed during this 30-min terminal assay. Experiments
performed using medium removed from endothelial cells and added to
Na2S yielded identical results
(data not shown). Sulfhemoglobin formation was greater in
hypoxic-reoxygenated cells at 60 min of treatment than in control
cells. If Na2S was added at 20 h
of reoxygenation, when most of the hemoglobin has returned to its
ferric (Hb3+) state, no
sulfhemoglobin was formed in either control or treated cells. Addition
of the antioxidants trolox (100 µM) or ascorbate (100 µM) did not
significantly affect sulfhemoglobin production under these conditions
(Table 1). However, addition of 100 µM
-tocopherol to the growth medium of BAEC, followed by washing away
any excess
-tocopherol before initiation of reoxygenation or normal
cell incubation with hemoglobin, significantly increased sulfhemoglobin
formation after 60 min of reoxygenation or 60 min of incubation with
normal BAEC (Table 1).
|
| |
DISCUSSION |
|---|
|
|
|---|
Recently reported animal and human studies have shown that a number of organs can be the target of toxicity when chemically or genetically altered hemoglobins are administered (1, 15, 20, 46). Endothelial cells, because of their primary position in the vasculature, are considered to be a target of damage after hemoglobin administration (8, 27, 29), as well as after ischemia-reperfusion (45, 30). Endothelial cells are also a source of a variety of oxidants, under normal and ischemic conditions (24, 34, 49). Because the level of these oxidants may vary during changes in physiological states, it is important to understand how the toxicity of heme proteins may vary in accord with the oxidant status, which may be encountered during administration of a hemoglobin-based oxygen carrier. In addition, it may be important to understand a more generalized phenomenon of heme-related toxicity that may proceed in the presence of endogenous heme proteins under a variety of pathophysiological states, such as ischemia-reperfusion (16, 19).
In this model, lactate production and the gross toxicity of hypoxia-reoxygenation toward BAEC were found to correlate with the duration of the hypoxic period. These results are consistent with data obtained previously in rabbit aortic endothelial cells (24) and with data obtained from ischemic tissue in other models (10, 12, 28). Decreases in ATP levels, changes in calcium flux, fatty acid release, and lipid peroxidation were also observed in this model using rabbit aortic endothelial cells (24).
Hemoglobin cross-linked at its
-subunits (
100 µM) did not
significantly increase toxicity in control or hypoxic-reoxygenated cells. However, at these levels, hemoglobin was found to significantly increase lipid peroxidation above the level of peroxidation induced by
hypoxia-reoxygenation alone. Although lipid peroxides may be expected
to cause cell death at high concentrations (32), lower levels of lipid
peroxidation have been shown to be associated with aberrant cell
signaling, inflammatory processes, and other physiological changes
(39). In addition, heme proteins have been shown to exhibit
pseudoenzymatic production of a variety of eicosanoids, lipid
peroxides, and similar products (13, 15, 22, 41). The reported
toxicities of cross-linked hemoglobin (15), which are also more subtle
than death of exposed vascular cells, may involve inflammatory or
signaling processes by one of these mechanisms.
One mechanism of lipid peroxidation by hemoglobin has been shown to
involve the highly reactive ferryl oxidation state, which has been
shown to abstract an allylic hydrogen from unsaturated fatty acids
(21). Another mechanism may involve heme loss and subsequent release of
iron. Because neither desferrioxamine nor EDTA exhibited an effect on
conjugated diene formation in this system, it was assumed that heme
iron loss from the cross-linked
-DBBF under our mild experimental
conditions was negligible. This is not surprising, since cross-linking
of hemoglobin with the reagent bis(3,5-dibromosalicyl)fumarate tends to
stabilize the hemoglobin molecule and to minimize heme loss (44).
Both ferrylhemoglobin, which can be detected by optical spectroscopy (48), and a globin-associated radical, which can be detected by electron paramagnetic resonance (25), are known to be formed via the reaction of oxy- and methemoglobin with hydrogen peroxide. In vitro, the concentration of hydrogen peroxide that is necessary to produce similar changes is 2-10 times the concentration of hemoglobin (2). Under our experimental conditions, however, no hydrogen peroxide was added to the media except that produced by cells themselves, <10 µM (Fig. 2). This is therefore an example of a biological oxidation of hemoglobin that mimics the more familiar reactions of hemoglobin seen in simpler mixtures (5, 11, 18). Recent studies suggest a mechanism composed of three steps that account for the oxidation of hemoproteins by peroxide: 1) initial oxidation of oxy- to ferrylheme, 2) autoreduction of ferryl intermediate to ferricheme, and 3) reaction of ferricheme with additional peroxide to regenerate the ferryl intermediate, creating a pseudoperoxidase catalytic cycle (3).
It is also possible that lipid peroxidation, which is a free radical
chain reaction, provides both the target of hemoglobin oxidation and an
alternate source of electrons, lipid hydroperoxides (13), which can
cause cyclic oxidation and reduction of hemoglobin. Although lipid
peroxidation can be terminated normally by reaction with an antioxidant
such as
-tocopherol (21) or through destruction of hydroperoxides by
glutathione peroxidase (42), the presence of hemoglobin may amplify the
level of peroxidation that takes place before termination occurs (21).
In these experiments,
-tocopherol, which has been shown to localize
to the cell membrane (24), was ineffective in preventing hemoglobin
oxidation (Table 1).
Antioxidants administered at various times during ischemia or
reperfusion in vivo have variable effectiveness in reducing reperfusion
injury, depending on a multitude of conditions, including the duration
of ischemia, the age of the animal, and the model studied
[for review see Reimer and Jennings (35)]. In addition, traditional "antioxidants," depending on their oxidation
potential in relation to other reactants, may behave as oxidants (14), as has been demonstrated for
-tocopherol in low-density lipoprotein (43) and ascorbate or glutathione in the presence of oxyhemoglobin (19). In general, the presence of a redox active
hemoglobin complicates a tissue model, which already includes
fluctuating levels of superoxide, hydrogen peroxide, organic peroxides,
and nitric oxide. Hemoglobin consumes glutathione either directly or
indirectly, through oxidative stress to the cell, and is oxidized in
the presence of
-tocopherol (19). Although the amount of glutathione
loss was relatively small (5-7%) in the presence of 400 µM
-DBBF, as contrasted to that which may be observed in disease states
(47), the additive toxicity of oxidants is of concern both at high
concentrations of hemoglobin and at lowered levels of cellular defenses.
Ferrylhemoglobin has been shown to be toxic to a number of different cell types, including endothelial cells (18, 30). Its presence has recently been detected in normal human blood (40), raising possible implications for highly reactive hemoglobin species in ischemia-reperfusion injury and in the development of atherosclerosis. In this model, ferrylhemoglobin formation after addition of hemoglobin in the media of hypoxic-reoxygenated cells was substantially greater than that produced in the media of normal endothelial cells. Production of ferrylhemoglobin was transient after the addition of hemoglobin, and no ferrylhemoglobin production could be detected at 20 h of reoxygenation when most of the hemoglobin present was in the form of methemoglobin. It has not yet been determined which cellular oxidants react with hemoglobin to produce the Hb4+ oxidation states nor the changes in their levels in endothelial cells over time. We are currently investigating the effects of lipid peroxides, nitric oxide, and other cellular oxidants on hemoglobin oxidation and on toxicity.
In conclusion, in an endothelial cell model of hypoxia-reoxygenation,
-DBBF hemoglobin, a blood substitute, does not increase cell death
at doses below 100 µM. At 60 µM, hemoglobin causes a reduction in
hydrogen peroxide concentration and an increase in lipid peroxidation
above that induced by hypoxia-reoxygenation alone. Coincubation of this
hemoglobin and endothelial cells causes transient oxidation of the
protein to its highly reactive and toxic ferryl species in a time frame
that corresponds closely with hydrogen peroxide production and lipid
peroxidation. In addition, hemoglobin depletes glutathione, a primary
antioxidant defense system against peroxide toxicity, and is not
effectively counteracted by water or lipid soluble antioxidants.
Hemoglobin may therefore represent a potential oxidative stress, with
associated toxicities, to exposed cells, as may other heme proteins
when they come in contact with tissue under pathological conditions
such as blunt injury or myocardial ischemia.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Francine Wood for technical assistance.
| |
FOOTNOTES |
|---|
The opinions and assertions contained herein are the scientific views of the authors of this article and are not to be construed as policy of the United States Food and Drug Administration.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: A. I. Alayash, Bldg. 29, Rm. 112, 8800 Rockville Pike, Bethesda, Maryland 20892 (E-mail: Alayash{at}cber.fda.gov).
Received 1 July 1998; accepted in final form 3 March 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Adamson, J. G.,
and
C. Moore.
Hemolink, an o-raffinose crosslinked hemoglobin-based oxygen carrier.
In: Blood Substitutes: Principles, Methods, Products, and Clinical Trials, edited by T. M. S. Chang. Basel: Karger Landes Systems, 1998, p. 62-81.
2.
Alayash, A. I.
Effects of intra- and intermolecular crosslinking on the free radical reactions of bovine hemoglobins.
Free Radic. Biol. Med.
18:
295-301,
1995[Medline].
3.
Alayash, A. I.,
B. A. Brockner-Ryan,
R. F. Eich,
J. S. Olson,
and
R. E. Cashon.
Reactions of sperm whale myoglobin with hydrogen peroxide: effects of distal pocket mutations on the formation and stability of the ferryl intermediate.
J. Biol. Chem.
274:
2029-2037,
1999
4.
Alayash, A. I.,
and
R. E. Cashon.
Hemoglobin and free radicals: implications for the development of a safe blood substitute.
Mol. Med. Today
1:
122-127,
1996.
5.
Alayash, A. I.,
J. C. Fratantoni,
C. Bonaventura,
J. Bonaventura,
and
E. Bucci.
Consequences of chemical modifications on the free radical reactions of human hemoglobin.
Arch. Biochem. Biophys.
298:
114-120,
1992[Medline].
6.
Alayash, A. I.,
J. C. Fratantoni,
C. Bonaventura,
J. Bonaventura,
and
R. E. Cashon.
Nitric oxide binding to human ferrihemoglobins cross-linked between either
or
subunits.
Arch. Biochem. Biophys.
303:
332-338,
1993[Medline].
7.
Aucoin, M. M.,
R. Barhoumi,
D. T. Kochevar,
H. J. Granger,
and
R. C. Burghardt.
Oxidative injury of coronary venular endothelial cells depletes intracellular glutathione and induces HSP 70 mRNA.
Am. J. Physiol.
268 (Heart Circ. Physiol. 37):
H1651-H1658,
1995
8.
Balla, G.,
H. S. Jacob,
J. Balla,
M. Rosenberg,
K. Nath,
F. Apple,
J. W. Eaton,
and
G. M. Vercellotti.
Ferritin: a cytoprotective antioxidant strategem of endothelium.
J. Biol. Chem.
267:
18148-18153,
1992
9.
Berzofsky, J. A.,
J. Peisach,
and
W. E. Blumberg.
Sulfheme proteins. I. Optical and magnetic properties of sulfmyoglobin and its derivatives.
J. Biol. Chem.
246:
3367-3377,
1971
10.
Boveris, A.,
and
B. Chance.
The mitochondrial generation of hydrogen peroxide: general properties and effect of hyperbaric oxygen.
Biochem. J.
134:
707-716,
1973[Medline].
11.
Cashon, R. E.,
and
A. I. Alayash.
Reaction of human HbA0 and two cross-linked derivatives with hydrogen peroxide: differential behavior of the ferryl intermediate.
Arch. Biochem. Biophys.
316:
461-469,
1995[Medline].
12.
Cino, M.,
and
R. F. Del Maestro.
Generation of hydrogen peroxide by brain mitochondria: the effect of reoxygenation following postdecapitative ischemia.
Arch. Biochem. Biophys.
269:
623-638,
1989[Medline].
13.
Ciuffi, M.,
L. Tarlini,
S. Mugnai,
S. Franchi-Micheli,
and
L. Zilletti.
Hemoglobin affects lipid peroxidation and prostaglandin E2 formation in rat corticocerebral tissues in vitro.
Biochem. Pharmacol.
52:
97-103,
1996[Medline].
14.
Decker, E. A.
Phenolics: prooxidants or antioxidants?
Nutr. Rev.
55:
396-398,
1997[Medline].
15.
Everse, J.,
and
N. Hsia.
The toxicities of native and modified hemoglobins.
Free Radic. Biol. Med.
22:
1075-1099,
1997[Medline].
16.
Galaris, D.,
L. Eddy,
A. Arduini,
E. Cadenas,
and
P. Hochstein.
Mechanisms of reoxygenation injury in myocardial infarction: implications of a myoglobin redox cycle.
Biochem. Biophys. Res. Commun.
160:
1162-1168,
1989[Medline].
17.
Giulivi, C.,
and
K. J. A. Davies.
A novel antioxidant role for hemoglobin. The comproportionation of ferrylhemoglobin with oxyhemoglobin.
J. Biol. Chem.
265:
19453-19460,
1990
18.
Goldman, D. W.,
R. J. Brey III,
D. Yeh,
B. A. Brockner-Ryan,
and
A. I. Alayash.
Acellular hemoglobin-mediated oxidative stress toward endothelium: a role for hemoglobin oxidation product, the ferryl iron.
Am. J. Physiol.
275 (Heart Circ. Physiol. 44):
H1046-H1053,
1998
19.
Gorbunov, N. V.,
N. M. Elsayed,
E. R. Kisin,
A. V. Kozlov,
and
V. E. Kagan.
Air blast-induced pulmonary oxidative stress: interplay among hemoglobin, antioxidants, and lipid peroxidation.
Am. J. Physiol.
272 (Lung Cell. Mol. Physiol. 16):
L320-L334,
1997
20.
Hess, J. R.
Alternative oxygen carriers.
Curr. Opin. Hematol.
3:
492-497,
1996[Medline].
21.
Kanner, J.,
and
S. Harel.
Lipid peroxidation and oxidation of several compounds by H2O2 activated metmyoglobin.
Lipids
20:
625-628,
1985[Medline].
22.
Kuhn, H.,
R. Gotze,
T. Schewe,
and
S. M. Rapoport.
Quasi-lipoxygenase activity of haemoglobin: a model for lipoxygenases.
Eur. J. Biochem.
120:
161-168,
1981[Medline].
23.
Marbach, E. P.,
and
M. H. Weil.
Rapid enzymatic measurement of blood lactate and pyruvate.
Clin. Chem.
13:
314,
1967[Abstract].
24.
McLeod, L.,
and
A. Sevanian.
Lipid peroxidation and modification of lipid composition in an endothelial cell model of ischemia and reperfusion.
Free Radic. Biol. Med.
23:
680-694,
1997[Medline].
25.
Miller, Y. I.,
S. M. Altamentova,
and
N. Shaklai.
Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin.
Biochemistry
36:
12189-12198,
1997[Medline].
26.
Moncada, S.
Nitric oxide in the vasculature: physiology and pathophysiology.
Ann. NY Acad. Sci.
811:
60-69,
1997
27.
Motterlini, R.,
R. Foresti,
K. Vandegriff,
M. Intaglietta,
and
R. M. Winslow.
Oxidative-stress response in vascular endothelial cells exposed to acellular hemoglobin solutions.
Am. J. Physiol.
269 (Heart Circ. Physiol. 38):
H648-H655,
1995
28.
Neely, J. R.,
and
D. Feuvray.
Metabolic products and myocardial ischemia.
Am. J. Pathol.
102:
282-291,
1981[Abstract].
29.
Nolte, D.,
A. Botlar,
S. Pickelman,
E. Bouskela,
and
K. Messmer.
Effects of diaspirin-cross-linked hemoglobin (DCLHb) on the microcirculation of striated skin muscle in the hamster: a study on safety and toxicity.
J. Lab. Clin. Med.
130:
314-327,
1997[Medline].
30.
Ochi, H.,
I. Morita,
and
S. Murota.
Roles of glutathione and glutathione peroxidase in the protection against endothelial cell injury induced by 15-hydroperoxyeicosatetraenoic acid.
Arch. Biochem. Biophys.
294:
407-411,
1992[Medline].
31.
Ortiz de Motellano, P. R.
Catalytic sites of hemoprotein peroxidases.
Annu. Rev. Pharmacol. Toxicol.
32:
89-107,
1992[Medline].
32.
Pacifici, E. H. K.,
L. L. McLeod,
H. Peterson,
and
A. Sevanian.
Linoleic acid hydroperoxide-induced peroxidation of endothelial cell phospholipids and cytotoxicity.
Free Radic. Biol. Med.
17:
285-295,
1993.
33.
Panter, S. S.,
K. D. Vandegriff,
P. O. Yan,
and
R. F. Regan.
Assessment of hemoglobin-dependent neurotoxicity: alpha-alpha crosslinked hemoglobin.
Artif. Cells Blood Substit. Immobil. Biotechnol.
22:
399-413,
1994[Medline].
34.
Panus, P. C.,
R. Radi,
P. H. Chumley,
R. H. Lillard,
and
B. A. Freeman.
Detection of H2O2 release from vascular endothelial cells.
Free Radic. Biol. Med.
14:
217-223,
1993[Medline].
35.
Reimer, K. A.,
and
R. B. Jennings.
Preconditioning: definitions, proposed mechanisms, and implications for myocardial protection in ischemia and reperfusion.
In: Myocardial Protection. The Pathophysiology of Reperfusion and Reperfusion Injury, edited by D. M. Yellon,
and B. Jennings. New York: Raven, 1992, chapt. 8, p. 165-185.
36.
Sasaki, K.,
S. Bannai,
and
N. Makino.
Kinetics of hydrogen peroxide elimination by human umbilical vein endothelial cells in culture.
Biochim. Biophys. Acta
1380:
275-288,
1998[Medline].
37.
Sevanian, A.,
H. N. Hodis,
J. Hwang,
L. L. McLeod,
and
H. Peterson.
Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL.
J. Lipid Res.
36:
1971-1986,
1995[Abstract].
38.
Snyder, S. R.,
E. V. Welty,
R. Y. Walder,
L. A. William,
and
J. A. Walder.
HbXL99
. A hemoglobin derivative that is cross-linked between the
-subunit is useful as a blood substitute.
Proc. Natl. Acad. Sci. USA
84:
7280-7284,
1987
39.
Suzuki, Y. J.,
H. J. Forman,
and
A. Sevanian.
Oxidants as stimulators of signal transduction.
Free Radic. Biol. Med.
22:
269-285,
1997[Medline].
40.
Svistunenko, D. A.,
R. P. Patel,
S. V. Voloshchenko,
and
M. T. Wilson.
The globin-based free radical of ferryl hemoglobin is detected in normal human blood.
J. Biol. Chem.
272:
7114-7121,
1997
41.
Takenaka, K.,
N. F. Kassell,
P. L. Foley,
and
K. S. Lee.
Oxyhemoglobin-induced cytotoxicity and arachidonic acid release in cultured bovine endothelial cells.
Stroke
24:
839-846,
1993
42.
Tappel, A. L.,
and
H. Zalkin.
Inhibition of lipid peroxidation in microsomes by vitamin E.
Nature
4705:
35,
1960.
43.
Upston, J. M.,
J. Neuzil,
and
R. Stocker.
Oxidation of LDL by recombinant human 15-lipoxygenase: evidence for alpha-tocopherol-dependent oxidation of esterified core and surface lipids.
J. Lipid Res.
37:
2650-2661,
1996[Abstract].
44.
Vandergriff, K. D.
Stability and toxicity of hemoglobin solutions.
In: Blood Substitutes: Physiological Basis of Efficacy, edited by R. M. Winslow,
K. D. Vandergriff,
and M. Intaglietta. Boston, MA: Birkhäuser, 1995, p. 105-132.
45.
Vaughan, D. M.,
J. R. Koke,
and
N. Bittar.
Ultrastructure, peroxisomes and lipid peroxidation in reperfused myocardium.
Cytobios
55:
71-80,
1988[Medline].
46.
Viele, M.,
R. Weiskopf,
and
D. Fisher.
Recombinant hemoglobin doesn't affect renal function in humans: analysis of safety and pharmacokinetics.
Anaesthesiology
86:
846-858,
1977.
47.
Walmsley, S. L.,
L. M. Winn,
M. L. Harrison,
J. P. Uetrecht,
and
P. G. Wells.
Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications.
AIDS
11:
1689-1697,
1997[Medline].
48.
Winterbourn, C. C.
Reactions of superoxide with hemoglobin.
In: CRC Handbook of Methods for Oxygen Radical Research, edited by R. A. Greenwald. Boca Raton, FL: CRC, 1985, p. 137-141.
49.
Zulueta, J. J.,
R. Sawhney,
F. S. Yu,
C. C. Cote,
and
P. M. Hassoun.
Intracellular generation of reactive oxygen species in endothelial cells exposed to anoxia-reoxygenation.
Am. J. Physiol.
272 (Lung Cell. Mol. Physiol. 16):
L897-L902,
1997
50.
Zweier, J. L.,
P. Kuppusamy,
and
G. A. Lutty.
Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues.
Proc. Natl. Acad. Sci. USA
85:
4046-4050,
1988
This article has been cited by other articles:
![]() |
F. D'Agnillo and A. I. Alayash Redox cycling of diaspirin cross-linked hemoglobin induces G2/M arrest and apoptosis in cultured endothelial cells Blood, December 1, 2001; 98(12): 3315 - 3323. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D'Agnillo and A. I. Alayash Interactions of hemoglobin with hydrogen peroxide alters thiol levels and course of endothelial cell death Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1880 - H1889. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |